Acción 0A87 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Takeda Pharmaceutical Company Limited London S.E.

Acciones

0A87

US8740602052

Mercado cerrado - London S.E.
Otros sitios de cotización
 16:28:32 23/05/2024 		Varia. Cinco días. Varia. 1 de enero.
13,07 USD +0,12 % Gráfico intradía de Takeda Pharmaceutical Company Limited +0,11 % -8,12 %
06/06 La unidad farmacéutica de Takeda se asocia con HEALWELL AI para el análisis de la evidencia en el mundo real del angioedema hereditario MT
06/06 Torrent Pharma firma un acuerdo con la japonesa Takeda para comercializar un fármaco contra los trastornos relacionados con la acidez en la India MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K
Former Takeda Employee Pleads Guilty to Defrauding Company
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
GSK blood cancer drug nearly halves risk of death in late-stage trial
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM
Takeda Gets CHMP Approval for Recombinant ADAMTS13
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
Pharmakonzern Takeda plant Abbau von bis zu 120 Stellen in Opfikon
BHP pursuit of Anglo American highlights corporate-led UK M&A upswing
Takeda Pharmaceutical : Other items which are provided electronically
Evotec steigt aus Gentherapie-Geschäft aus - Ergebniseinbruch zum Jahresstart
TAKEDA PHARMACEUTICAL : Form 6-K
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 4502
  4. Acción 0A87
  5. Noticias Takeda Pharmaceutical Company Limited
  6. Otros idiomas